Founded in 2021, AIVIS is an AI-driven digital pathology company delivering cell-level biomarker quantification for precision oncology. Through proprietary AI models deployed as SaMD, AIVIS enhances the accuracy and reproducibility of cancer diagnosis and treatment.
Its flagship solution, Qanti IHC, enables quantitative analysis down to HER2 ultralow, addressing diagnostic uncertainty caused by inter-observer variability in manual scoring. Designed by AIVIS’s in-house pathologists and AI researchers, the HER2 model has been clinically validated to improve pathologist agreement by up to 39.6%.
Following GMP and ISO 13485 certification in 2024, AIVIS has obtained two MFDS approvals for its digital medical devices in Korea. Through strategic collaborations with Philips and AstraZeneca, AIVIS currently serves 20+ medical institutions and is expanding globally. AIVIS is advancing a biomarker-driven diagnostic ecosystem through integration with digital pathology platforms.
Advanced diagnostics and data technologies
Advanced bioinformatics and artificial intelligence for biotechnology
Qanti® Discovery will be applied as an RUO WSI-based biomarker analysis platform for ADC development. Animal and human WSI will be analyzed to quantify target expression and explore candidate cut-offs and patient/sample enrichment criteria.